//img.uscri.be/pth/e56429e3ce57d4a6de225ebce0bcbe3cffc4a629
Cette publication ne fait pas partie de la bibliothèque YouScribe
Elle est disponible uniquement à l'achat (la librairie de YouScribe)
Achetez pour : 158,24 € Lire un extrait

Téléchargement

Format(s) : PDF

avec DRM

Targeted Therapies in Cancer

De

From its introduction, oncological chemotherapy has been encumbered by its poor selectivity because most antiproliferative drugs are toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. The resultant problems with unwanted side effects are compounded by difficulties in predicting the desired effectivity of chemotherapy in individual patients.


This unsatisfactory situation has driven intensive research and development towards more specific and less toxic anticancer drugs over the last few decades. Several results of these efforts have reached the clinic and an even greater number are now in preclinical testing.


Common to all these targeted therapies is their interaction with defined molecules present on cancer cells, which adds various degrees of increased selectivity to their toxic effects. As a consequence, detecting the target molecule on tumors before therapy holds great diagnostic potential for predicting the efficacy of the drug and personalizing therapy.


This book aims to present translational scientists and clinicians with an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach.

Voir plus Voir moins
Contents Contents
Part I
1
2
3
4
5
6
7
8
Predîctîon o Tumor Behavîor
Vïï
Beyond Typîng and Gradîng: Target Analysîs în ïndîvîdualîzed Therapy as a New Challenge or Tumour Pathology . . . . .3 Hans H. Kreipe, Reinard von Wasieewski
Oncogenîc Sîgnalîng Pathways and Deregulated Target Genes . . . . . . . . . . . .7 Reinod Scäer, Anja Scramme, Oeg I. Tcernitsa, Cristine Sers
Predîctîve Pathology o Cytostatîc Drug Resîstance and New Antî-cancer Targets . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25 Manred Diete
Predîctîon o Response to Neoadjuvant Chemotherapy în Carcînomas o the Upper Gastroîntestînal Tract . . . .. . . . . . . . . . . . . . . . . . . . .33 Heinz Höler, Rupert Langer, Katja Ott, Gisea Keer
Resîstance-Assocîated Sîgnatures în Breast Cancer . . . . . . . . . . . . . . . . . . . . . . . .37 Baázs Györfy
Resîstance to Chemotherapy în Ovarîan Carcînoma . .. . . . . . . . . . . . . . . . . . . . .51 Hermann Lage, Carsten Denkert
Clînîcal, Bîologîcal, and Molecular Aspects o Metastasîs în Colorectal Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . .61 Urike Stein, Peter M. Scag
Predîctîon o EIcacy and Sîde Efects o Chemotherapy în Colorectal Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . .81 Jan Stoemacer
9
Vïïï
Part II
10
11
12
13
14
15
16
17
Contents
Proteomîc Expressîon Proilîng o Breast Cancer . . . .. . . . . . . . . . . . . . . . . . . . . . .89 Hans Neubauer, Tanja Fem, Cristina Scütz, Runa Speer, Eric Soomayer, André Scrattenoz, Micae A. Cai, Rafae Kurek
Targeted Therapy and Clînîcal Applîcatîons
Targeted Therapy and Blood–Braîn Barrîer . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . .123 Agnieszka Kore, Eckard hie
Cetuxîmab: Appraîsal o a Novel Drug Agaînst Colorectal Cancer . . . . . . . .135 Bert Hidebrandt, Piipp e Coutre, Annett Nicoaou, Konrad Köbe, Hanno Riess, Bernd Dörken
C-kît, GïST, and ïmatînîb . . . . . . . . . . . . . . . . . . . . . ... . . . . . . . . . . . . . . . . . . . . . . . . . .145 Jan Sie, Eckard hie
Antîbody Therapy în Non-Hodgkîn’s Lymphoma: The Role o Rîtuxîmab, 90Y-ïbrîtumomab Tîuxetan, and Alemtuzumab . . . . . . . . . . .153 homas Fietz, Eckard hie
Molecular and Clînîcal Aspects o Proteasome ïnhîbîtîon în the Treatment o Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . .165 Ivana Zavrski, Cristian Jakob, Martin Kaiser, Caudia Feissner, Urike Heider, Oran Sezer
ïndîvîdualîzed Target Therapy o Malîgnant Lymphomas: An Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... . . . . . . . . . . . . . .177 Ioannis Anagnostopouos
Antîangîogenesîs, Antî-VEGF(R) and Outlook . . . . . . .. . . . . . . . . . . . . . . . . . . . . .189 Iver Petersen
Morphologîcal Detectîon o Hormone and Growth Factor Receptors în Breast Cancer . . . . . . . . . . . . . . . . . . . . . . . .. . . . . . . . . . . . . . . . . . . . . . . . .201 Konrad Köbe
Contents
Part III
18
19
20
21
Prospects or Development
ïX
Antîgen-Specîic Cancer Vaccînes . . . . . . . . . . . . . . . . ... . . . . . . . . . . . . . . . . . . . . . .213 Uric Keioz
Therapeutîc Vaccînatîon or the Treatment o Malîgnant Melanoma . . . . .219 Peter Waden
Monoclonal and Recombînant Antîbodîes wîth T Cell Receptor-Lîke Reactîvîty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...229 Andreas Zieger, Pierre G. Couie, Barbara Ucańska-Zieger
New Molecular Therapy Targets în Acute Myeloîd Leukemîa . . . . . . . . . . . . .243 Utz Krug, Hubert Serve, Carsten Müer-Tidow, Ro M. Mesters, Björn Stefen, homas Bücner, Wogang E. Berde
http://www.springer.com/978-3-540-46090-9